[Diagnosis and treatment of insulinoma].
Arita
Yoshiyuki
Y
Department of Medical and Bioregulatory Science, Graduate School of Medicine Science, Kyushu University.
Ito
Tetsuhide
T
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D016461:Chemoembolization, Therapeutic; D003981:Diazoxide / Q000627:therapeutic use; D005215:Fasting; D005934:Glucagon; D006801:Humans; D007340:Insulinoma / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008299:Maleic Anhydrides / Q000627:therapeutic use; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D011137:Polystyrenes / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives; D014057:Tomography, X-Ray Computed; D009353:Zinostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001786:Blood Glucose; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D013004:Somatostatin; D005934:Glucagon; D009353:Zinostatin; D003981:Diazoxide